Navigating the treatment of RRMM with BCMA-directed therapies: Updates from COMy, ASCO and EHA 2025
Description
touchCONGRESS for touchHAEMATOLOGY and touchONCOLOGY
Listen to multiple myeloma expert Prof. Philippe Moreau review key data for BCMA-targeting agents in the treatment of relapsed/refractory multiple myeloma presented at the international Controversies in Multiple Myeloma (COMy), American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) 2025 congresses. Prof. Moreau is then joined by fellow experts Dr Paola Neri and Prof. Hermann Einsele to discuss how these data may apply in clinical practice.
Overview
- Data reviews with Prof. Moreau
- Expert panel discussions with Prof. Moreau, Dr Neri and Prof. Einsele on the themes below
Clinical themes
- Approved BCMA-directed therapeutic approaches
- Practical application of BCMA-directed therapies
- Future of treating RRMM: Emerging BCMA-directed therapies and combinations
The internationally renowned multiple myeloma expert faculty
- Prof. Philippe Moreau: Nantes, France
- Prof. Hermann Einsele: Würzburg, Germany
- Dr Paola Neri: Calgary, AB, Canada
This touchPODCAST is for HCPs outside of the USA.
This activity is funded by an independent medical education grant from GSK.
This activity is provided by touchIME.
touchIME is an EBAC® accredited provider.
For further information, visit our website: www.touchHAEMATOLOGY.com and www.touchONCOLOGY.com
United States
